Predicting Effectiveness of Light Treatment for Winter Seasonal Affective Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

41 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-11-30

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate a possible tool for predicting future effectiveness of bright light in treating seasonal affective disorder, winter subtype, and will examine secondary effects of bright light on cardiovascular risk factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low Intensity 'Blue Light' Treatment of Seasonal Affective Disorder

NCT01149135

Seasonal Affective Disorder

COMPLETED NA

30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder

NCT01462305

Seasonal Affective Disorder

COMPLETED NA

Light-Emitting Diode (LED) Light for Seasonal Affective Disorder (SAD) Treatment

NCT00114322

Seasonal Affective Disorder

UNKNOWN NA

Blue Enriched Versus Standard Light Treatment for Seasonal Affective Disorder(SAD)

NCT01048294

Seasonal Affective Disorder

COMPLETED NA

Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)

NCT00006517

Seasonal Affective Disorder Mood Disorders Depression

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The winter subtype of seasonal affective disorder (SAD) is characterized by episodes of major depression in the fall and winter, with remission of these episodes in the spring and summer. SAD disrupts the lives of millions of Americans, who experience symptoms such as restless agitation, increased appetite and weight gain, and reduced energy and motivation. Bright light treatment, while shown to be effective in improving SAD in 75% of cases, only causes a full remission in 50% of cases. If doctors had a diagnostic tool to determine which patients would respond to bright light therapy, they could make better decisions about whether to prescribe bright light as treatment. This study will examine a possible diagnostic tool-a single, 1-hour bright light session-for predicting improvement in SAD symptoms over an extended course of bright light treatment. Additionally, because many symptoms of SAD (like weight gain and sedentary lifestyle) correspond to cardiovascular risk, this study will examine whether bright light treatment correlates with improved cardiovascular health.

Participants with SAD will be randomly assigned to first receive a 1-hour session of either bright light or the placebo, red light. Then all participants will switch and receive a 1-hour session of the other type of light. Red light has been accepted as a placebo in previous SAD studies because it does not suppress melatonin or shift circadian rhythms. Before and after each light session, participants will have their SAD symptoms evaluated in a clinical interview and self-report measure. After these two light sessions, all participants will receive instructions for administering bright light treatment on their own at home. For the next 6 weeks, participants will administer the bright light to themselves for 1 hour every morning. Every week they will undergo clinical interviews by phone and will mail in self-report measures, some completed daily and some weekly, to the researchers. The participants will have checkups and interviews in person on Weeks 4 and 6. At the two time periods, SAD symptoms and indicators of cardiovascular risk, such as appetite and sleep loss, will be evaluated. The participant responses to bright light and red light at the initial session will be compared with the participant responses to the subsequent 6-week treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Participants will be given a 1-hour lab test of bright light treatment, then the bright light treatment for 6 weeks.

Bright light

Intervention Type DEVICE

One hour of exposure to bright light daily upon awakening for 6 weeks.

B

Participants will be given a 1-hour treatment of the red light placebo, then the bright light treatment for 6 weeks.

Red light placebo

Intervention Type DEVICE

One hour of exposure to red light.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bright light

One hour of exposure to bright light daily upon awakening for 6 weeks.

Intervention Type DEVICE

Red light placebo

One hour of exposure to red light.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Brite light III light box (Apollo) 10,000 lux. Dim red light box (Apollo) 50 lux.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Current major depressive disorder, by structured diagnostic interview (SCID), or current bipolar II disorder, if no prior history of rapid cycling, by SCID
* Prior history of major depressive disorder or bipolar II disorder with seasonal specifier, by SCID
* Score of 21 or greater on Hamilton Rating Scale for Depression - Seasonal Affective Disorder Version (SIGH-SAD), met at three time points (informed consent session, 24 hours prior to first light therapy session, and at first light therapy session)

Exclusion Criteria

* Current bipolar I disorder, psychotic disorder, or cognitive disorder, by SCID
* Illicit drug use in the past year, by self-report, or alcohol abuse by SCID
* History of systemic lupus erythematosus
* History of heart attack or stroke
* No antidepressant, mood stabilizer, or antipsychotic medication treatment 30 days before treatment
* Current occupation involves shift work
* Current sensitivity to bright light or vision problems not correctable by glasses, by self-report
* Inability to distinguish colors or see stars at night because of increased light sensitivity, by self-report
* Current suicidal ideation, by self-report during SCID interview
* Women of childbearing potential who are pregnant, nursing, or trying to become pregnant. Female participants of childbearing potential must agree to one of the following types of birth control: oral, transdermal, or implantable hormonal contraceptives; intrauterine device; diaphragm plus spermicide; or female condom plus spermicide.

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No